Loading…
X4 Pharmaceuticals, Inc. is projected to rise to $4.93 by 2027, a +24% move from its current price of $3.98. XFOR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.85 | $3.99 | $4.12 | +0.13% |
| Aug 4 | $3.81 | $3.99 | $4.18 | +0.25% |
| Aug 5 | $3.77 | $4.00 | $4.23 | +0.38% |
| Aug 6 | $3.74 | $4.00 | $4.28 | +0.50% |
| Aug 7 | $3.72 | $4.01 | $4.32 | +0.63% |
| Aug 8 | $3.69 | $4.01 | $4.35 | +0.76% |
| Aug 9 | $3.67 | $4.02 | $4.39 | +0.88% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.67 | $4.02 | $4.39 | +0.88% |
| Week 2 | $3.57 | $4.05 | $4.59 | +1.78% |
| Week 3 | $3.50 | $4.09 | $4.77 | +2.67% |
| Week 4 | $3.45 | $4.12 | $4.92 | +3.58% |
| Week 5 | $3.41 | $4.16 | $5.07 | +4.50% |
| Week 6 | $3.38 | $4.20 | $5.21 | +5.42% |
| Week 7 | $3.35 | $4.23 | $5.35 | +6.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
X4 Pharmaceuticals, Inc., a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company has license agreements with Abbisko Therapeutics Co Ltd.
to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals, Inc. trades under the ticker XFOR and is currently priced at $3.90. Its market capitalization stands at $367.85M and it is ranked 3315 by market cap. The price outlook is bullish over the long term, with notable upside in the 2030s and beyond.
For example, the 2030 average is $5.01 with a 28.4% ROI, the 2040 average is $11.01 with a 182.4% ROI, and the 2050 average is $19.83 with a 408.5% ROI.
A major floor 21.6% below — a decisive break under it would weaken the trend.
The nearest floor, 7.5% below — buyers have tended to step in here.
The nearest ceiling, 17.3% above — a clean break opens room to run.
A major ceiling 28.1% above — clearing it would confirm fresh momentum.
Key XFOR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XFOR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.97 | Buy | $3.96 | Buy |
| MA 10 | $3.88 | Buy | $3.94 | Buy |
| MA 20 | $3.93 | Buy | $3.95 | Buy |
| MA 50 | $4.00 | Sell | $3.99 | Sell |
| MA 100 | $4.07 | Sell | $3.98 | Buy |
| MA 200 | $3.86 | Buy | $4.35 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.69 | Neutral |
| Stoch RSI (14) | 93.19 | Sell |
| CCI (20) | 28.68 | Neutral |
| Williams %R (14) | -11.76 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 2.05 | Buy |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 88.24 | Sell |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 61.76 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 4.03 | Sell |
| ADX (14) | 6.81 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is neutral. RSI14 is 50 and the 50-day simple moving average is $4.07 while the 200-day simple moving average is $3.83. The price faces a near-term framework with a support at $3.71 and a resistance at $4.67. The 30-day price range spans from $2.96 to $5.14.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.99 | $3.98 | $6.12 | 0% | Neutral | |
| $3.85 | $4.93 | $6.72 | +24% | Bullish | |
| $3.90 | $5.17 | $7.37 | +30% | Bullish | |
| $3.89 | $5.32 | $7.85 | +34% | Bullish | |
| $3.70 | $5.19 | $7.89 | +30% | Bullish | |
| $3.63 | $5.22 | $8.13 | +31% | Bullish | |
| $3.81 | $5.59 | $8.91 | +41% | Bullish | |
| $4.65 | $6.98 | $11.35 | +75% | Bullish | |
| $5.01 | $7.67 | $12.70 | +93% | Bullish | |
| $4.86 | $7.59 | $12.79 | +91% | Bullish | |
| $5.70 | $9.72 | $17.59 | +144% | Bullish | |
| $9.11 | $18.20 | $36.49 | +357% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.99 | $3.98 | $5.10 | +0.00% |
| September 2026 | $3.73 | $4.44 | $5.46 | +11.67% |
| October 2026 | $3.72 | $4.46 | $5.56 | +0.42% |
| November 2026 | $3.78 | $4.57 | $5.75 | +2.45% |
| December 2026 | $3.96 | $4.82 | $6.12 | +5.37% |
Click any year to see its month-by-month XFOR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
X4 Pharmaceuticals, Inc.'s 2026 outlook centres on $3.98, within a $2.99 to $6.12 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, XFOR could reach as high as $6.72, with a base case around $4.93 and support toward $3.85 — roughly +24% from $3.98. Buyers look set to stay in control over this stretch.
Expect XFOR to range from $3.90 to $7.37 through 2028. The $5.17 average target implies a +30% move from current prices. That is up +5% on the projected 2027 average. Momentum favours further upside here.
The XFOR price prediction for 2029 points to an average of $5.32 (low $3.89, high $7.85) — a potential gain of +34% on today's $3.98. Buyers look set to stay in control over this stretch.
In 2030, XFOR is projected to trade between $3.70 and $7.89, averaging $5.19 — a potential gain of +30% from today's $3.98. That is -2% versus the projected 2029 average. Momentum favours further upside here.
X4 Pharmaceuticals, Inc.'s 2031 outlook centres on $5.22, within a $3.63 to $8.13 range. That is up +1% on the projected 2030 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, XFOR could reach as high as $8.91, with a base case around $5.59 and support toward $3.81 — roughly +41% from $3.98. Momentum favours further upside here.
Expect XFOR to range from $4.65 to $11.35 through 2033. The $6.98 average target implies a +75% move from current prices. That is up +25% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The XFOR price prediction for 2034 points to an average of $7.67 (low $5.01, high $12.70) — a potential gain of +93% on today's $3.98. Momentum favours further upside here.
In 2035, XFOR is projected to trade between $4.86 and $12.79, averaging $7.59 — a potential gain of +91% from today's $3.98. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
X4 Pharmaceuticals, Inc.'s 2040 outlook centres on $9.72, within a $5.70 to $17.59 range. That is up +28% on the projected 2035 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2050, XFOR could reach as high as $36.49, with a base case around $18.20 and support toward $9.11 — roughly +357% from $3.98. Buyers look set to stay in control over this stretch.
Investing $1,000 in XFOR today (≈ 251.256281 XFOR) could be worth
$4,573.38
+$3,573.38 (+357%) by 2050 · US Dollar
Based on the average projected XFOR price of $18.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XFORwould be worth at today's price.
$1,000 invested in XFOR on Jul 31, 2025 (≈ 595.238114 XFOR) would be worth
$2,369.05
+$1,369.05 (+136.9%) today · 2.37× · US Dollar
Based on a XFOR entry price of $1.68 vs. today's $3.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.85 | $1,033.77 | +3.4% |
| 1 month ago | $4.09 | $974.3 | -2.6% |
| 3 months ago | $4.19 | $949.88 | -5.0% |
| 6 months ago | $3.98 | $1,000 | -0.0% |
| 1 year ago | $1.68 | $2,369.05 | +136.9% |
| All time (5.0y) ago | $169.8 | $23.44 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XFOR forecast.
Our base-case forecast reaches $8.00 around 2040.
Implied market cap at $8.00: $754.56M
The multi-year forecast shows a bullish trajectory from 2027 onward, with substantial upside projected into the late 2020s and beyond. The 2027 average is $4.85 (ROI 24.3%), 2028 average $5.36 (ROI 37.4%), and 2029 average $5.49 (ROI 40.8%), leading into 2030 with an average of $5.01 (ROI 28.4%). In the longer horizon, 2040 forecasts an average of $11.01 (ROI 182.4%), and 2050 forecasts an average of $19.83 (ROI 408.5%).
The sentiment shifts to BULLISH from 2027 onward. These numbers are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $5.01 with a range from $3.37 to $8.06 and an ROI of 28.4%, with sentiment BULLISH.
The long-term forecast shows bullish sentiment from 2027 onward, with a 2050 average of $19.83 and ROI 408.5%, though 2026 is neutral; these are estimates and not guarantees.
Yes, the 2050 forecast lists an average of $19.83 and a max of $43.89, indicating the potential to approach or exceed $20 within the forecast horizon; the 2040 average is $11.01.
RSI14 is 50; SMA50 is $4.07; SMA200 is $3.83; the 30-day range is $2.96 to $5.14; support is $3.71 and resistance is $4.67.
Current price is $3.90 and market capitalization is $367.85M.
X4 Pharmaceuticals, Inc. Community Discussion
0Share your X4 Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.